233 related articles for article (PubMed ID: 27547177)
1. The Isotropic Fractionator as a Tool for Quantitative Analysis in Central Nervous System Diseases.
Repetto IE; Monti R; Tropiano M; Tomasi S; Arbini A; Andrade-Moraes CH; Lent R; Vercelli A
Front Cell Neurosci; 2016; 10():190. PubMed ID: 27547177
[TBL] [Abstract][Full Text] [Related]
2. Short-term lithium treatment promotes neuronal survival and proliferation in rat striatum infused with quinolinic acid, an excitotoxic model of Huntington's disease.
Senatorov VV; Ren M; Kanai H; Wei H; Chuang DM
Mol Psychiatry; 2004 Apr; 9(4):371-85. PubMed ID: 14702090
[TBL] [Abstract][Full Text] [Related]
3. Exploring the neuroprotective effects of montelukast on brain inflammation and metabolism in a rat model of quinolinic acid-induced striatal neurotoxicity.
Tassan Mazzocco M; Murtaj V; Martins D; Schellino R; Coliva A; Toninelli E; Vercelli A; Turkheimer F; Belloli S; Moresco RM
J Neuroinflammation; 2023 Feb; 20(1):34. PubMed ID: 36782185
[TBL] [Abstract][Full Text] [Related]
4. Glial cell line-derived neurotrophic factor attenuates the excitotoxin-induced behavioral and neurochemical deficits in a rodent model of Huntington's disease.
Araujo DM; Hilt DC
Neuroscience; 1997 Dec; 81(4):1099-110. PubMed ID: 9330371
[TBL] [Abstract][Full Text] [Related]
5. Rat cortico-striatal sagittal organotypic slice cultures as
McCaughey-Chapman A; Connor B
Heliyon; 2022 Sep; 8(9):e10819. PubMed ID: 36193519
[TBL] [Abstract][Full Text] [Related]
6. Neurogenesis in the striatum of the quinolinic acid lesion model of Huntington's disease.
Tattersfield AS; Croon RJ; Liu YW; Kells AP; Faull RL; Connor B
Neuroscience; 2004; 127(2):319-32. PubMed ID: 15262322
[TBL] [Abstract][Full Text] [Related]
7. Injectable hydrogels providing sustained delivery of vascular endothelial growth factor are neuroprotective in a rat model of Huntington's disease.
Emerich DF; Mooney DJ; Storrie H; Babu RS; Kordower JH
Neurotox Res; 2010 Jan; 17(1):66-74. PubMed ID: 19588214
[TBL] [Abstract][Full Text] [Related]
8. NMDA and non-NMDA receptor-stimulated IkappaB-alpha degradation: differential effects of the caspase-3 inhibitor DEVD.CHO, ethanol and free radical scavenger OPC-14117.
Nakai M; Qin Z; Wang Y; Chase TN
Brain Res; 2000 Mar; 859(2):207-16. PubMed ID: 10719066
[TBL] [Abstract][Full Text] [Related]
9. Antiepileptic and Neuroprotective Effects of Oleamide in Rat Striatum on Kainate-Induced Behavioral Seizure and Excitotoxic Damage via Calpain Inhibition.
Nam HY; Na EJ; Lee E; Kwon Y; Kim HJ
Front Pharmacol; 2017; 8():817. PubMed ID: 29209207
[TBL] [Abstract][Full Text] [Related]
10. c-Jun N-terminal kinase signaling pathway in excitotoxic cell death following kainic acid-induced status epilepticus.
Spigolon G; Veronesi C; Bonny C; Vercelli A
Eur J Neurosci; 2010 Apr; 31(7):1261-72. PubMed ID: 20345908
[TBL] [Abstract][Full Text] [Related]
11. Transplants of Encapsulated Rat Choroid Plexus Cells Exert Neuroprotection in a Rodent Model of Huntington's Disease.
Borlongan CV; Thanos CG; Skinner SJM; Geaney M; Emerich DF
Cell Transplant; 2007 Nov; 16(10):987-992. PubMed ID: 28866919
[TBL] [Abstract][Full Text] [Related]
12. Cellular delivery of CNTF but not NT-4/5 prevents degeneration of striatal neurons in a rodent model of Huntington's disease.
Emerich DF; Bruhn S; Chu Y; Kordower JH
Cell Transplant; 1998; 7(2):213-25. PubMed ID: 9588602
[TBL] [Abstract][Full Text] [Related]
13. A new derivative of valproic acid amide possesses a broad-spectrum antiseizure profile and unique activity against status epilepticus and organophosphate neuronal damage.
White HS; Alex AB; Pollock A; Hen N; Shekh-Ahmad T; Wilcox KS; McDonough JH; Stables JP; Kaufmann D; Yagen B; Bialer M
Epilepsia; 2012 Jan; 53(1):134-46. PubMed ID: 22150444
[TBL] [Abstract][Full Text] [Related]
14. Quinolinic acid-induced increases in calbindin D28k immunoreactivity in rat striatal neurons in vivo and in vitro mimic the pattern seen in Huntington's disease.
Huang Q; Zhou D; Sapp E; Aizawa H; Ge P; Bird ED; Vonsattel JP; DiFiglia M
Neuroscience; 1995 Mar; 65(2):397-407. PubMed ID: 7777157
[TBL] [Abstract][Full Text] [Related]
15. Dexmedetomidine protects neurons from kainic acid-induced excitotoxicity by activating BDNF signaling.
Chiu KM; Lin TY; Lee MY; Lu CW; Wang MJ; Wang SJ
Neurochem Int; 2019 Oct; 129():104493. PubMed ID: 31220473
[TBL] [Abstract][Full Text] [Related]
16. Blockade of quinolinic acid-induced neurotoxicity by pyruvate is associated with inhibition of glial activation in a model of Huntington's disease.
Ryu JK; Kim SU; McLarnon JG
Exp Neurol; 2004 May; 187(1):150-9. PubMed ID: 15081596
[TBL] [Abstract][Full Text] [Related]
17. Age-dependent differences in survival of striatal somatostatin-NPY-NADPH-diaphorase-containing interneurons versus striatal projection neurons after intrastriatal injection of quinolinic acid in rats.
Figueredo-Cardenas G; Chen Q; Reiner A
Exp Neurol; 1997 Aug; 146(2):444-57. PubMed ID: 9270055
[TBL] [Abstract][Full Text] [Related]
18. Effect of neuronal excitotoxicity on Munc18-1 distribution in nuclei of rat hippocampal neuron and primary cultured neuron.
Zhang YP; Wan P; Wang HQ; Zhao H; Xu YX; Yang R; Zhu CQ
Neurosci Bull; 2011 Jun; 27(3):163-72. PubMed ID: 21614099
[TBL] [Abstract][Full Text] [Related]
19. Mutually protective actions of kainic acid epileptic preconditioning and sublethal global ischemia on hippocampal neuronal death: involvement of adenosine A1 receptors and K(ATP) channels.
Plamondon H; Blondeau N; Heurteaux C; Lazdunski M
J Cereb Blood Flow Metab; 1999 Dec; 19(12):1296-308. PubMed ID: 10598933
[TBL] [Abstract][Full Text] [Related]
20. Administration of recombinant human Activin-A has powerful neurotrophic effects on select striatal phenotypes in the quinolinic acid lesion model of Huntington's disease.
Hughes PE; Alexi T; Williams CE; Clark RG; Gluckman PD
Neuroscience; 1999; 92(1):197-209. PubMed ID: 10392842
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
